GlassScriptPhysician profile
David Kellen
NPI 1396889671
$2,554.88
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $344 · 2021: $376 · 2022: $246 · 2023: $363 · 2024: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $449.58 | 2019-2024 | Veozah |
| Amgen INC. | $305.86 | 2019-2024 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $298.37 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $228.48 | 2019-2024 | |
| Pfizer INC. | $222.41 | 2019-2024 | |
| Novo Nordisk INC | $160.85 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $136.76 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $114.22 | 2020-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $111.14 | 2019-2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.45 | 2020-2022 | |
| Amarin Pharma, INC. | $63.99 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $42.62 | 2019-2020 | |
| Esperion Therapeutics, INC. | $41.08 | 2021-2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $35.33 | 2024 | Voquezna |
| Exact Sciences Corporation | $33.84 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $31.13 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.99 | 2019 | |
| Allergan, INC. | $27.71 | 2019 | |
| Dexcom, INC. | $27.54 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $25.81 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.07 | 2020 | |
| Genentech USA, INC. | $13.80 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.38 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.07 | 2021 | |
| Therapeuticsmd, INC. | $12.82 | 2020 | |
| Abbott Laboratories | $12.00 | 2022 | |
| Gilead Sciences, INC. | $11.44 | 2020 | |
| Zyla Life Sciences, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kellen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.